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Background: The assumption of consistency, defined as agreement between direct and indirect sources of
evidence, underlies the increasingly popular method of network meta-analysis. This assumption is often evaluated
by statistically testing for a difference between direct and indirect estimates within each loop of evidence. However,
the test is believed to be underpowered. We aim to evaluate its properties when applied to a loop typically found
in published networks.
Methods: In a simulation study we estimate type I error, power and coverage probability of the inconsistency test
for dichotomous outcomes using realistic scenarios informed by previous empirical studies. We evaluate test
properties in the presence or absence of heterogeneity, using different estimators of heterogeneity and by
employing different methods for inference about pairwise summary effects (Knapp-Hartung and inverse variance
methods).
Results: As expected, power is positively associated with sample size and frequency of the outcome and negatively
associated with the presence of heterogeneity. Type I error converges to the nominal level as the total number of
individuals in the loop increases. Coverage is close to the nominal level in most cases. Different estimation methods
for heterogeneity do not greatly impact on test performance, but different methods to derive the variances of the
direct estimates impact on inconsistency inference. The Knapp-Hartung method is more powerful, especially in the
absence of heterogeneity, but exhibits larger type I error. The power for a ‘typical’ loop (comprising of 8 trials and
about 2000 participants) to detect a 35% relative change between direct and indirect estimation of the odds ratio
was 14% for inverse variance and 21% for Knapp-Hartung methods (with type I error 5% in the former and 11% in
the latter).
Conclusions: The study gives insight into the conditions under which the statistical test can detect important
inconsistency in a loop of evidence. Although different methods to estimate the uncertainty of the mean effect
may improve the test performance, this study suggests that the test has low power for the ‘typical’ loop.
Investigators should interpret results very carefully and always consider the comparability of the studies in terms of
potential effect modifiers.
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The validity of results from network meta-analysis de-
pends on the plausibility of the transitivity assumption;
that is the comparability of studies informing the treat-
ment comparisons with respect to the distribution of ef-
fect modifiers [1-3]. Lack of transitivity in a network can
create statistical disagreement between direct and vari-
ous sources of indirect evidence, often termed inconsist-
ency [4]. Statistical evaluation of consistency is possible
only when there are ‘closed loops of evidence’ in the net-
work. The recent increase in applications of network
meta-analysis has emphasised the need for methods to
evaluate consistency and has motivated the development
of statistical models [5-7] and methods [8-11].
Empirical evidence suggests that the prevalence of statis-
tically significant loop inconsistency ranges from 2% to
17% [12-14]. However, little is known about factors that
impact on the detection of inconsistency. As expected, the
power to detect inconsistency is positively associated with
the number and size of trials, and both power and type I
error increase when a fixed-effect model is assumed [15].
It has been argued that the presence and magnitude of
heterogeneity (within comparison variability) in a loop of
evidence can impact on inferences made about inconsist-
ency and empirical evidence has confirmed these claims
by showing that different estimators of the heterogeneity
variance are likely to have a considerable impact [14]. Fi-
nally, previous studies showed that inconsistency occurs
more frequently in loops where one of the comparisons is
informed only by one trial [14,16,17].
Although there are indications that the presence, mag-
nitude and estimation method of heterogeneity might
influence the detection of inconsistency, this association
has not been studied extensively. For instance, the im-
pact of two alternative methods to express uncertainty
about the pairwise summary effects (inverse variance
and Knapp-Hartung method [18,19]) remains unclear. It
has been shown that the Knapp-Hartung method out-
performs inverse variance in coverage for the summary
effect and that it is insensitive to the estimator of the
heterogeneity used [20,21]. We anticipate that differ-
ences in the properties of the two methods will impact
on the estimation of inconsistency.
The aim of this paper is to explore factors that affect
the detection of inconsistency in a three-treatment net-
work for a dichotomous outcome. The factors that we
explore are associated with the amount of data available
in the loop (such as number, size and distribution of tri-
als across comparisons, frequency of events), the hetero-
geneity variance in the pairwise comparisons (presence
or absence and estimation method) and the method for
inference about pairwise summary effects (inverse vari-
ance or Knapp-Hartung). We consider only log-odds ra-
tio (LOR) as the effect size of interest. We conduct asimulation study considering realistic scenarios including
only two-arm trials and we estimate type I error, power
and coverage probability for the test of consistency. The
simulation scenarios are informed by two previous em-
pirical studies; a large collection of 303 loops from pub-
lished networks of interventions [14] and a study about




Consider a simple scenario with three competing treat-
ments A, B and C and that there are trials that compare
directly all three possible pairs of treatments. Evaluation
of inconsistency in a triangular network requires first
the estimation of three direct summary effects for each
pairwise comparison. We denote the effect sizes (i.e.
LORs) for the three pairs of treatments as μ^DIRAB ; μ^
DIR
AC and







superscript denotes the source of evidence (‘DIR’ for direct
here or ‘IND’ indirect later) and the subscript denotes the
treatment comparison. For any given comparison (e.g. BC)
we estimate the indirect mean treatment effect, μ^INDBC , as a
simple contrast of two direct estimates involving the third
treatment, and we compare it with the corresponding dir-
ect estimate μ^DIRBC .




ABC ¼ μ^DIRBC −μ^INDBC
  ¼ μ^DIRBC −μ^DIRAC þ μ^DIRAB 
with variance
v^IFABC ¼ v^DIRBC þ v^ INDBC ¼ v^DIRBC þ v^DIRAC þ v^DIRAB ð1Þ
The direction of the estimated IF is irrelevant to the
evaluation of inconsistency and only the magnitude of
its absolute value is of interest. The subscript in IF
∧
ABC
refers to the loop in which inconsistency is estimated.






p eN 0; 1ð Þ;
with a critical region |z| ≥ za/2. In the present study we
select a = 0.05.
Estimation of variance
Equation (1) suggests that the method used to estimate
the variance of the direct treatment effects vDIRAB ; v
DIR
AC and
vDIRBC will play an important role in the performance of
the z-test for inconsistency. We consider two methods
to estimate the direct variances and examine how they
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is the usual inverse-variance method and the second
method is an alternative approach proposed by Knapp
and Hartung [19].
In a pairwise meta-analysis we either assume that trials
estimate a single underlying effect size (fixed-effect model)
or that the study-specific underlying effect sizes are differ-
ent but drawn from the same distribution (random effects
model) with heterogeneity τ2. Under the latter scenario, it
is common to assume that heterogeneity is the same for all
comparisons being made, i.e. τ2AB ¼ τ2AC ¼ τ2BC ¼ τ2 . We
adopt this assumption throughout the paper and we esti-
mate τ2 using the DerSimonian and Laird estimator [23].
In the inverse variance approach, the direct variances
are simple functions of the sampling variances of the in-
dividual trials and the heterogeneity variance τ2. Suppose
that KAB, KAC and KBC trials inform the AB, AC and BC
comparisons respectively. If the sampling variances were
the same for all trials (σ2), the inverse variance estimator










Consequently, v^IFABC depends on the heterogeneity and
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Figure 1 Histograms of the within-loop heterogeneity, mean treatme
Mean treatment effects are displayed on the absolute of the log-odds ratio
method. Histograms are plotted for 40 published networks of evidence [14An alternative approach to estimate each direct variance,
and consequently vIFABC , is the approach proposed by
Knapp and Hartung [19]. They derive the variance v^DIRAB as
the ratio of a generalised Q statistic divided by the product
of the degrees of freedom (KAB − 1) and the sum of the
random-effects study weights [24]. It has been shown that
the performance of this method is not influenced by the
choice of the heterogeneity estimator [19,21,25,26].
In summary, we estimate the variances of the direct
pairwise summary effects by employing two different strat-
egies: the inverse variance method using DerSimonian and
Laird estimator (IVDL) and the Knapp-Hartung method
with the DerSimonian and Laird estimator (KHDL). When
a comparison is addressed by a single trial (so that the
loop includes 3 trials in total) estimation of heterogeneity
is impossible. In these cases we use the fixed-effect model
(by setting τ2 to be zero) and consequently both IVDL and
KHDL methods would yield exactly the same results.Simulation study
Empirical evidence to inform simulation scenarios
To inform the simulation scenarios we use a large collec-
tion of complex networks of interventions [14]. Figure 1
summarises some of the attributes of 303 loops from 40
published networks with dichotomous outcomes ana-
lysed using the LOR scale. The majority of the pairwise
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nt effect, number of trials per meta-analysis and inconsistency.
scale. Heterogeneity is estimated with the DerSimonian and Laird
].
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0.75). In 91% of the loops the common within-loop hetero-
geneity using the DerSimonian and Laird estimator is less
than 0.5 and it is estimated at zero (when rounded to the
second decimal) in 51% of the loops. The median IF is 0.36
with IQR (0.15, 0.80). The median number of trials per loop
is 8 IQR (6, 14) and the median loop sample size is 2256
IQR (1026, 18890); the respective median number of trials
and sample size per comparison are 2 IQR (1, 4) and 706
IQR (255, 2997). Most networks had a subjective primary
outcome (43%), whereas 35% and 22% of the networks had
reasonably objective outcomes (e.g. cause-specific mortal-
ity, major morbidity event) and all-cause mortality out-
comes respectively. The majority of the networks (63%)
compared pharmacological interventions versus placebo.
In the case of such a comparison type and subjective out-
come, Turner et al. suggest that the distribution of the
heterogeneity is reasonably approximated by a log-normal
τ2 ~ LN(−2.13, 1.582), with median τ2 = 0.12 and IQR
(0.03, 0.34) [22]. Our empirical data seem to match the
predictive distribution suggested by Turner et al. [22] (τ2 ~
LN(−2.13, 1.582)), though more data are needed since
we have only 55 common within-loop heterogeneities
estimated in networks with pharmacological interven-
tions versus placebo comparison type and subjective
outcome.
Simulation scenarios
We use subscripts k1, k2 and k3 to refer to the three com-
parisons AB, AC and BC respectively, so that k1 = 1, …,
KAB, k2 = 1, …, KAC and k3 = 1, …, KBC, where KAB, KAC,
KBC represent the number of trials included in AB, AC
and BC comparisons respectively. We examine both bal-
anced direct comparisons, i.e. all comparisons include the
same number of trials KAB = KAC = KBC = K = 1, …, 7,
and imbalanced direct comparisons, i.e. each comparison
is informed by a different number of trials with KAB = 1,
KAC = 4, KBC = 7. Both balanced and imbalanced scenarios
were selected, informed by the empirical data. In particu-
lar, the imbalanced scenario included a comparison with a
single trial, because the majority (196 out of 303) of ob-
served loops had this characteristic. We then set the sec-
ond comparison to include a large number of trials (7
trials) and for the third comparison we selected the median
between the two extremes (4 trials). We restrict our ana-
lysis to dichotomous outcome data measured using odds-
ratio (OR) due to its mathematical properties [27-29].
Based on the results from the empirical study [14], we as-
sume ORAB = 1/exp(0.32) = 0.73 and ORAC = 1 the rela-
tive treatment effects for AB and AC respectively. We
compute the OR for the BC comparison as
ORBC ¼ exp log ORACð Þ− log ORABð Þ þ IFABCf g:We select values IFABC = {0, 0.3, 0.45, 0.6, 1} to cover a
range of plausible values for inconsistency as suggested by
empirical data (Figure 1d). We consider two different distri-
butions for heterogeneity that pertain to a subjective out-
come (the most frequently reported outcome in our data)
and all-cause mortality for comparisons between pharma-
cological interventions and placebo; according to [22] these
are τ2 ~ LN(−2.13, 1.582) and τ2 ~ LN(−4.06, 1.452) (me-
dian τ2 = 0.02 with (IQR 0.01, 0.04)).
For each combination of OR, IFABC, and τ
2 we simulate
the trial-specific underlying relative treatment effects from
a normal distribution as
LORAB;k1eN LORAB; τ2ð Þ , LORAC;k2eN LORAC; τ2ð Þ
and LORBC;k3eN LORBC; τ2ð Þ:
Then, we generate arm-level data for each trial k1, k2
and k3. Without loss of generality we describe how to
obtain arm-level data for an AB trial. We assume equal
sample sizes across arms, that is nA;k1 ¼ nB;k1 ¼ n. The
observed IQR for arm sample size in our empirical data
is 51 to 270, and to represent moderate and large studies
we generated studies with n ~ U(50, 150) and n ~ U
(150, 300). We also considered n ~ U(20, 50) to generate
data for very small studies. The number of events per
arm, denoted with rA;k1 and rB;k1 are drawn from two
binomial distributions rA;k1eBðnA;k1 ; pA;k1Þ and rB;k1eB
ðnB;k1 ; pB;k1Þ where pA;k1 and pB;k1 are the probabil-
ities of the outcome in each trial arm. To define these
probabilities we make assumptions about the average risk
(AR) of the outcome in the trial assuming both frequent
and rare events. To simulate from frequent event rates we
draw from a uniform distribution ARAB;k1eU 0:25; 0:75ð Þ
and for rare events ARAB;k1eU 0:05; 0:15ð Þ:
Then the event probabilities in the arms are obtained










For frequent events and assuming no heterogeneity,
the expected mean variance of LOR ranges from 0.04 to
0.25 depending on sample size. Variances for LOR for
rare events range from 0.10 to 0.69.
















If the simulated number of events in one of the study
arms is zero, we add 0.5 to the cells of the 2 × 2 table.
We repeat this process for all KAB trials and then we
perform a random-effects meta-analysis to obtain the
summary effect size μ^DIRAB . We follow the same process
for comparisons AC and BC and then we estimate the
inconsistency factor. Table 1 presents a summary of the
simulation scenarios considered.
For each scenario we analyse 1000 simulated triangular
networks. Assuming a 5% significance level, we estimate
the power of the test when true inconsistency is present
(P(|z| ≥ 1.96|IF ≠ 0) and type I error when the null hy-
pothesis is true (P(|z| ≥ 1.96|IF = 0). We compute the
coverage probability for the confidence interval (CI) of
inconsistency, which is the probability that the estimated




KAB = KAC = KBC = 1, …, 7
Imbalanced direct
comparisons
KAB = 1, KAC = 4, KBC = 7 (and KAB = 1, KAC = 4,
KBC = 3 for the typical loop)
Treatment effects
Comparison AB ORAB = 0.73
Comparison AC ORAC = 1
Comparison BC ORBC = exp{log(ORAC) − log(ORAB) + IFABC}
Inconsistency in the network
Inconsistency Factor IFABC = {0, 0.3, 0.45, 0.6, 1}
Heterogeneity in the network
Subjective outcome τ2 ~ LN(−2.13, 1.582)
All-cause mortality
outcome
τ2 ~ LN(−4.06, 1.452)
Trial arm size nA;k1 ¼ nB;k1 ¼ n
 	
Small n ~ U(20, 50)
Moderate n ~ U(50, 150)
Large





ARAB;k1eU 0:25; 0:75ð Þ
Average risk for rare
events
ARAB;k1eU 0:05; 0:15ð Þ





methodsimulations in the freely available software R 2.15.2 [30]
using the self-programmed sims.fun function, which we
have made available online (http://www.mtm.uoi.gr/index.
php/material-from-publications-software-and-protocols).
In addition to the scenarios described above we also
consider an extra scenario representing the ‘typical’ loop;
that is a loop with the characteristics most commonly
encountered in our collection of 303 loops. We specified
this such that one comparison was informed by a single
trial and the median number of studies per loop was 8,
in line with the empirical evidence. The median loop
sample size is 2300 (i.e. average trial arm size 144) [14].
Consequently, a loop with KAB = 1, KAC = 4, KBC = 3,




Figure 2 and Additional file 1: Figure S1 display the esti-
mated type I error for equal and different numbers
of trials across comparisons. In general, type I error is
close to the nominal level for IVDL, but larger than 5%
for many scenarios analysed with KHDL. The KHDL
method generally yields smaller variances for IF, leading
to larger type I errors (average type I error across all sce-
narios for IVDL: 0.07, average type I error across all sce-
narios for KHDL: 0.10, see also Figure 2a and b). Type I
error converges to the nominal level more rapidly when
τ2 = 0 for both IVDL and KHDL methods. The overall
type I error approaches the nominal level as the number
of trials increases for the same trial size. For example,
for frequent events type I error reaches on average the
nominal level when K = 5 for small sample sizes, and
K = 4 for moderate and large sample sizes. In Table 2
we provide the type I error values for various simulation
scenarios. When the total number of individuals in-
cluded in the network ranges from 2400 to 3000 (i.e.
close to the empirically estimated median loop size) type
I error lies between 0.06 and 0.08. Type I error deviates
from 5% considerably when an equal and small number
of trials is considered across comparisons for all trial
sizes (see Figure 2a ,b and Table 2).
For rare events, type I error departs from 5% more
than it does for frequent events (Figure 2). Type I error
is lower than its nominal level in most cases for IVDL
especially when τ2 = 0, probably due to overestimation of
τ2. The KHDL method results again in considerably lar-
ger type I errors, which is probably due to the small vari-
ances of the mean treatment effects (average type I error
across all scenarios for IVDL: 0.05, average type I error
across all scenarios for KHDL: 0.08, see Figure 2c and
d). Type I error is closer to the nominal level for IVDL
when τ2 ≠ 0 for all sample sizes. All methods tend to im-
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Figure 2 Type I error by sample sizes, frequency of events and loop sample size. We assume equal number of trials per comparison
(KAB = KAC = KBC = K = 1, …, 7) in the presence (τ
2 ≠ 0) and absence (τ2 = 0) of heterogeneity. Circled points correspond to loops with K = 1 for
which a fixed-effects model is employed. The region within the horizontal dotted lines defines the confidence interval for the 5% nominal level.
IVDL: inverse variance method using the DerSimonian and Laird estimator, KHDL: Knapp-Hartung method with the DerSimonian and
Laird estimator.
Table 2 Type I error, power and coverage probability by sample size and number of trials
Balanced scenario (KAB = KAC = KBC = K) Imbalanced scenario




Type I error (IF = 0)
n ~ U(20,50) 0.07 0.07 0.06 0.04 0.05 0.05 0.04 0.06
n ~ U(50,150) 0.10 0.07 0.06 0.06 0.05 0.06 0.04 0.08
n ~ U(150,300) 0.13 0.07 0.05 0.06 0.06 0.04 0.05 0.06
Power (IF = 0.6)
n ~ U(20,50) 0.13 0.15 0.18 0.23 0.27 0.33 0.37 0.16
n ~ U(50,150) 0.25 0.30 0.42 0.52 0.62 0.70 0.76 0.32
n ~ U(150,300) 0.42 0.54 0.70 0.79 0.84 0.88 0.89 0.49
Coverage Probability (IF = 0.6)
n ~ U(20,50) 0.96 0.96 0.97 0.98 0.97 0.97 0.97 0.97
n ~ U(50,150) 0.95 0.96 0.97 0.96 0.96 0.96 0.96 0.95
n ~ U(150,300) 0.93 0.95 0.94 0.94 0.96 0.95 0.95 0.95
Results are presented for frequent events and aggregated over different assumptions for heterogeneity and methods to estimate the variances of the mean
treatment effects. In bold we present results from loops in which the total number of individuals is between 2400 and 3000. n: sample size, K: number of trials.
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Additional file 1: Figure S1).
Statistical power
Figure 3 and Additional file 2: Figure S2 present the power
for IF = {0.3, 0.45, 0.6, 1} for both frequent and rare events
when equal (Figure 3) and different (Additional file 2:
Figure S2) numbers of trials are included in compari-
sons. As expected, the overall power increases both with
number of trials included in the loop and with the trial
size. Power increases when the trials included in a loop
have comparable sample sizes. Results are aggregated
over all estimation methods for heterogeneity and the
different methods to estimate the variance of the direct
summary effects. In Table 2 we provide the power values
for various simulation scenarios when IF = 0.6 and fre-
quent events are considered. When the total number of
individuals included in the network ranges from 2400 to
3000, power ranges between 0.54 and 0.70 when an equal
number of trials is assumed across comparisons but drops
to 0.32 when each comparison has a different number of
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Figure 3 Power by inconsistency factor, frequency of events and loop
moderate and large) assuming equal number of trials per comparison (KAB
assumptions for heterogeneity and methods to estimate the variance of th
pertains to the case where there is a single trial per comparison and a fixedtrials across comparisons affects the estimation of incon-
sistency variance. This has an impact on power and the
test is more powerful when trials are distributed uniformly
across comparisons. Comparing, for example, the power
of the test for the balanced scenario KAB = 4, KAC = 4,
KBC = 4 and the imbalanced scenario KAB = 1, KAC = 4,
KBC = 7 (each with 12 trials in the loop), power is higher
when the distribution of trials is balanced across compari-
sons (ranges from 0.23 to 0.79) rather than imbalanced
(ranges from 0.16 to 0.49) (see Table 2). The comparison
of frequent (Figure 3a) and rare (Figure 3b) events indi-
cates that power is larger for frequent events (average
power across all scenarios for frequent events: 0.44, aver-
age power across all scenarios for rare events: 0.25). Rare
events are associated with larger uncertainty for the direct
mean treatment effects and thus the chances of identifying
potentially important inconsistency decrease. It should be
noted that the first summary result of each power curve
pertains to the case where there is only one trial per com-
parison and heterogeneity is set to be zero. This has an
impact on monotonicity especially when IF is low and trial
size is large.)
iduals in the loop
b rare eventse size
ple size
le size












































sample size. Power is presented for different sample sizes (small,
= KAC = KBC = K = 1,…, 7). Results are aggregated over different
e mean treatment effect. The first summary result in each power curve
-effects model is employed. IF: inconsistency factor.
Table 3 Power of the test for inconsistency aggregated over sample size and number of trials
Heterogeneity No heterogeneity
IF = 0.3 IF = 0.45 IF = 0.6 IF = 1 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1
Frequent Events
IVDL 0.17 0.26 0.36 0.59 0.20 0.38 0.52 0.77
KHDL 0.19 0.27 0.37 0.60 0.27 0.44 0.58 0.80
Rare Events
IVDL 0.10 0.15 0.21 0.38 0.09 0.16 0.25 0.49
KHDL 0.13 0.18 0.24 0.41 0.16 0.23 0.33 0.55
Results are presented for equal number of trials across comparisons. IF: inconsistency factor, IVDL: inverse variance method with the DerSimonian and Laird
estimator, KHDL: the Knapp-Hartung method with the DerSimonian and Laird estimator.
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KHDL methods. For frequent events the power to detect
inconsistency does not vary significantly with the method
used to estimate heterogeneity or to express uncertainty on
the summary effects although the Knapp-Hartung method
is marginally more powerful, especially in the absence of
heterogeneity. This is because, in many cases, the Knapp-
Hartung method estimates smaller inconsistency variances
compared with the inverse variance method. The median
inconsistency standard error is 0.33 (IQR 0.21, 0.50) for
KHDL and 0.40 (IQR 0.27, 0.57) for IVDL. As expected,
when there is no heterogeneity, there is less uncertainty as-
sociated with each pairwise effect and the power to detect
inconsistency increases for all IF values (Table 3).
The impact of heterogeneity is similar when the out-
come is rare (average power across all IF values for
KHDL: 0.24, average power across all IF values for IVDL:
0.21, see Table 3). Table 3 shows that the advantage of
KHDL method when heterogeneity is zero becomes
more pronounced for rare events (average power across
all IF values for KHDL: 0.32, average power across all IF
values for IVDL: 0.25, see Table 3).
Coverage probability and bias
We assess how often the 95% CI for inconsistency in-
cludes the assumed IF value used to generate the data.
We plot the coverage probability for the 95% CI of IF in
Additional file 3: Figure S3. The coverage probability is
close to the nominal level (95%) for most settings. RareTable 4 Power of the inconsistency test aggregated over sam
Heterogeneity
IF = 0.3 IF = 0.45 IF = 0.6 IF =
Fr
IVDL 0.10 0.15 0.23 0.42
KHDL 0.11 0.17 0.24 0.42
IVDL 0.08 0.10 0.14 0.25
KHDL 0.11 0.12 0.16 0.28
IVDL: inverse variance method with the DerSimonian and Laird estimator, KHDL: Knevents are associated with larger uncertainty and therefore
provide slightly higher coverage than frequent events
(average coverage across all scenarios for frequent events:
0.95, average coverage across all scenarios for rare events:
0.97). In Table 2 we provide the coverage values for vari-
ous simulation scenarios when IF = 0.6. When the total
number of individuals included in the network ranges
from 2400 to 3000, coverage ranges from 0.95 to 0.96
(Table 2). Coverage does not change considerably when an
equal or different number of trials is assumed across com-
parisons (Additional file 4: Figure S4).
In Additional file 5: Figure S5 and Additional file 6:
Figure S6 we present the average relative bias IF^−IF
 =IF 	
for IF > 0. Relative bias decreases with the total number of
individuals included in the network, the total number of tri-
als, and the assumed IF value.
Tables 5 and 6 present the coverage probability for
the 95% CI of IF using different methods to express un-
certainty on the summary effects. The KHDL method
reduces slightly the chances of including the true incon-
sistency factor in the 95% CI of IF, especially when there
is no heterogeneity, as the mean treatment effects be-
come more precise.Characteristics of the inconsistency test in a ‘typical’ loop
of evidence
The type I error in the ‘typical’ loop is 5% and 7% for
subjective and all-cause mortality outcomes using IVDLple size
No heterogeneity
1 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1
equent Events
0.13 0.23 0.38 0.68
0.19 0.31 0.44 0.73
Rare Events
0.07 0.11 0.17 0.35
0.12 0.17 0.25 0.44
app-Hartung method with the DerSimonian and Laird estimator.
Table 5 Coverage probability of the 95% confidence interval for the inconsistency factor (IF)
Heterogeneity No heterogeneity
IF = 0 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1 IF = 0 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1
Frequent Events
IVDL 0.90 0.94 0.94 0.94 0.93 0.96 0.98 0.97 0.97 0.97
KHDL 0.89 0.93 0.93 0.93 0.91 0.92 0.95 0.94 0.94 0.93
Rare Events
IVDL 0.93 0.96 0.96 0.97 0.96 0.97 0.98 0.99 0.98 0.96
KHDL 0.91 0.95 0.95 0.95 0.94 0.92 0.96 0.96 0.95 0.94
Results are aggregated over sample size and number of trials (assumed equal across comparisons). IVDL: inverse variance method with the DerSimonian and Laird
estimator, KHDL: Knapp-Hartung method with the DerSimonian and Laird estimator.
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http://www.biomedcentral.com/1471-2288/14/106and 11% and 12% using KHDL. The ‘typical’ loop of evi-
dence with all-cause mortality outcome has considerably
low power. The overall power ranges between 14% and
75% for IVDL and 21% to 78% for KHDL depending on
the magnitude of inconsistency. For a subjective out-
come that pertains to larger heterogeneity power de-
creases to 14%-63% for IVDL and in 20% to 65% for
KHDL. Coverage is close to the 95% nominal level (see
Table 7).
Discussion
The increased use of network meta-analysis should be
accompanied by caution when combining direct and in-
direct evidence via careful assessment of the consistency
assumption. Protocols of network meta-analyses should
present methods for the evaluation of inconsistency and
define strategies to be followed when inconsistency is
present. Several methodologies have been outlined in
the literature to test inconsistency [4-9]. In this study,
we evaluate the properties of the z-test for detecting in-
consistency comparing direct and indirect estimates in
triangular networks generating 1000 loops for each sce-
nario presented in Table 1. Although running more than
1000 simulations per scenario would have decreased the
Monte Carlo error, we believe the main conclusions
from our simulations are robust. Our scenarios are in-
formed by previous large-scale empirical studies and
hence are directly applicable [14,22]. We use a variety of
scenarios that involve the most commonly used meta-Table 6 Coverage probabilities of the 95% confidence interva
Heterogeneity
IF = 0 IF = 0.3 IF = 0.45 IF = 0.6 IF =
Frequent
IVDL 0.92 0.96 0.96 0.96 0.95
KHDL 0.91 0.95 0.96 0.95 0.94
Rare Ev
IVDL 0.95 0.96 0.97 0.98 0.98
KHDL 0.93 0.95 0.96 0.96 0.96
IVDL: inverse variance method with the DerSimonian and Laird estimator, KHDL: Knanalytic tools for statistical inference regarding heterogen-
eity and the uncertainty of the mean treatment effects.
The main advantage of this work is that it sheds light on
factors that might affect the detection of inconsistency
and have not been examined in the past, such as the use
of Knapp-Hartung variance for the direct summary effects.
Our main findings are summarized below.
 The assumption of consistency in network meta-
analysis is often evaluated performing a z-test within
each loop of evidence.
 The inconsistency test has low power for the ‘typical’
loop (comprising 8 trials and about 2000 partici-
pants) found in published networks. This study
suggests that the probability to detect inconsistency
when present is between 14% and 21% depending on
the estimation method.
 Power is positively associated with sample size and
frequency of the outcome, and negatively associated
with the underlying extent of heterogeneity.
 Using the Knapp-Hartung method to estimate
uncertainty around meta-analytic effects is slightly
more powerful than the inverse variance approach.
 Type I error converges to the nominal level as the
total number of individuals included in the loop
increases while coverage is close to the nominal level
for most studied scenarios.
 We recommend that investigators a) employ a
variety of methods to evaluate inconsistency, b)l for the inconsistency factor (IF)
No heterogeneity
1 IF = 0 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1
Events
0.97 0.98 0.98 0.97 0.97
0.93 0.96 0.95 0.95 0.93
ents
0.97 0.98 0.98 0.99 0.99
0.93 0.96 0.96 0.96 0.95
app-Hartung method with the DerSimonian and Laird estimator.
Table 7 Type I error, power and coverage probability for the inconsistency test in a ‘typical’ loop of evidence
Type I error Power Coverage probability
IF = 0 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1 IF = 0 IF = 0.3 IF = 0.45 IF = 0.6 IF = 1
All-cause mortality outcome (median (τ2) = 0.02)
IVDL 0.05 0.14 0.23 0.38 0.75 0.95 0.97 0.99 0.98 0.95
KHDL 0.11 0.21 0.32 0.46 0.78 0.89 0.94 0.93 0.92 0.90
Subjective outcome (median (τ2) = 0.11)
IVDL 0.07 0.14 0.23 0.34 0.63 0.94 0.96 0.96 0.97 0.95
KHDL 0.12 0.20 0.29 0.41 0.65 0.88 0.93 0.93 0.92 0.91
We assume a dichotomous frequent outcome, number of trials (K) per comparison KAB = 1, KAC = 4, KBC = 3 and the sample size per arm is drown from n ~ U(120,
160). IF: inconsistency factor, IVDL: inverse variance method with the DerSimonian and Laird estimator, KHDL: Knapp-Hartung method with the DerSimonian and
Laird estimator.
Veroniki et al. BMC Medical Research Methodology 2014, 14:106 Page 10 of 12
http://www.biomedcentral.com/1471-2288/14/106interpret the magnitude of the estimated inconsis-
tency factor and its confidence interval c) adopt a
sceptical stance towards statistically non-significant
test results unless the loop of evidence has many
data d) always consider the comparability of the
studies in terms of potential effect modifiers to infer
about the possibility of inconsistency
Our simulation study shows that the inconsistency test
has on average low power to detect inconsistency, in
particular for rare outcomes (i.e. for IF = 0.3 and large
trial sizes a rare outcome has event rate on average 0.10
IQR (0.07, 0.13)). Bruadbrn et al. [31] state that the
IVDL method may be “unsuitable when there are few
events” and that it should be avoided. In the absence of
heterogeneity and for a large number and size of trials
the overall power for inconsistency might be adequate.
A previous simulation study [15] also found that differ-
ent ways to evaluate inconsistency (e.g. Lu and Ades [6]
model, node-splitting method [9]) have low power in
particular under the random-effects models. Our study
suggests that power is improved if the Knapp-Hartung
method is used, especially in the absence of heterogen-
eity, although the type I error increases as well. This is
because the estimated uncertainty around inconsistency
is small with Knapp-Hartung method. These findings
agree with a previous simulation study, which showed
that when heterogeneity is zero the Knapp-Hartung
method yields a smaller variance for the mean treatment
effects than the inverse variance method [21].
Several methods have been suggested to estimate het-
erogeneity τ2 [32,33]. In the present study we also in-
cluded the restricted maximum likelihood [34] and the
empirical Bayes [35] estimators in conjunction with the
inverse variance approach. Although the three estima-
tors have different properties and performance in gen-
eral, they have been showed to have comparable bias
and mean squared error for estimating τ2 in the exam-
ined simulation scenarios (relatively small number of tri-
als for each pairwise meta-analysis (fewer than 7) andmedian heterogeneity τ2 = 0.12 are comparable [32]. Con-
sequently type I error, power and coverage were found
similar between the three methods (data not shown) and
we present results only from IVDL and KHDL. This
agrees with an empirical study that compared five different
estimators for the heterogeneity and showed that varia-
bility in the confidence intervals of the overall treatment
effect was quite negligible across 920 Cochrane meta-
analyses [36].
The inconsistency test, analogously to the heterogeneity
test, has low power and we recommend that the point es-
timate of inconsistency and its 95% confidence interval are
used instead to draw inferences about the presence and
magnitude of inconsistency. In cases where the test is
underpowered, the confidence intervals would include
zero, small and large inconsistency values and should be
interpreted as lack of evidence for or against the presence
of inconsistency. If a test must be used, one possibility is
to use a cut-off p-value of 0.10, as has been suggested for
the heterogeneity test in pairwise meta-analysis [37,38].
Empirical evidence showed that the observed disagree-
ment between direct and indirect comparisons is 1 in 10
loops, so this cut-point might be a reasonable choice [14].
In complex networks, instead of using multiple underpow-
ered z-test, global tests such as the design-by-treatment
test can be used, although power properties of the latter
are unknown.
Some limitations in our study need to be acknowledged.
We do not account for the possible impact of multi-arm
trials on inconsistency and we only reconsider triangular
networks. Our previous empirical study showed that a
large majority (85%) of published networks of interven-
tions involve trials with multiple arms, and that out of the
total 1173 trials included in all 40 networks 116 (10%)
were multi-arm trials. Further simulation studies are there-
fore needed to evaluate complex networks with multi-arm
trials. In our simulation study we assume that all compari-
sons in the network share the same amount of heterogen-
eity. Turner et al. [22] showed that different amounts of
heterogeneity can be expected for different outcomes or for
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non-pharmacological). Network meta-analyses typically
consider only one outcome and often compare interven-
tions of a similar nature. Hence the assumption of equal
heterogeneities is often clinically reasonable as well as be-
ing statistically convenient. Most comparisons in networks
comprise only few studies, making estimation of hetero-
geneity challenging. In case heterogeneity is believed to
vary across comparisons, we can assume different parame-
ters which should be restricted to conform to special rela-
tionships according to the consistency assumption [39].
Finally, a thorough investigation of all available methods
to evaluate inconsistency using realistic scenarios in-
formed by empirical evidence would be needed for com-
pleteness [5-7].
This is the second simulation study that suggests stat-
istical evaluation of inconsistency has low power [15]. In
our simulations we consider three-treatment networks
for simplicity but analyse them using methods typically
employed for network meta-analysis, e.g. assuming com-
mon heterogeneity in a one-stage analysis. As inconsist-
ency is a property of a closed loop, we believe that our
results are very relevant to full networks. Although our
study is limited to simple three-treatment networks in-
cluding only two-arm trials, we anticipate that the in-
consistency test would show similarly low power in
the presence of multi-arm studies: such studies are in-
ternally consistent and would contribute similar pair-
wise comparisons to evaluations of inconsistency.
Further simulation studies might be needed to learn
about the impact of assuming different heterogeneity
parameters for different comparisons. Reliable estima-
tion of different heterogeneity parameters will require a
minimum number of studies for each comparison, a
scenario which seldom occurs in published networks of
interventions. The Knapp-Hartung method has been
shown to be robust to the estimation of heterogeneity
[21] so we suspect that conclusions would be similar to
those drawn from the present study. It is therefore im-
perative for investigators to evaluate the assumption of
consistency using epidemiological strategies and com-
pare carefully the involved studies with respect to the
distribution of effect modifiers before embarking into
data synthesis [3,40].
Conclusions
Although the performance of the z-test for inconsistency
might vary according to the method used to estimate the
uncertainty of the overall mean treatment effect, the
power remains generally low for the loop of evidence
that typically features in networks of interventions. Par-
ticularly when data is sparse and a loop includes only a
few studies or the outcome is rare, the inconsistency test
is unlikely to be informative.Additional files
Additional file 1: Figure S1. Type I error by sample sizes, frequency of
events and loop sample size. Results are shown assuming different
number of trials (K) per comparison (KAB = 1, KAC = 4, KBC = 7).
The region within the horizontal dotted lines defines the confidence
interval for the 5% nominal level. IVDL: inverse variance method using
the DerSimonian and Laird estimator, KHDL: Knapp-Hartung method
with the DerSimonian and Laird estimator.
Additional file 2: Figure S2. Power by inconsistency factor, frequency
of events and loop sample size. We assume different number of trials (K)
per comparison (KAB = 1, KAC = 4, KBC = 7). Results are aggregated over
different assumptions for the heterogeneity and methods to estimate the
variances of the mean treatment effects. IF: inconsistency factor.
Additional file 3: Figure S3. Coverage probabilities of the 95%
confidence interval for the inconsistency factor, frequency of events
and loop sample size. We assume equal number of trials per comparison
(KAB = KAC = KBC = K = 1, …, 7). Results are aggregated over different
assumptions for the heterogeneity and methods to estimate the
variances of the mean treatment effects. The region within the horizontal
dotted lines defines the confidence interval for the 95% nominal level.
The first summary result in each coverage probability line pertains to the
case where there is a single trial per comparison and a fixed-effects
model is employed.
Additional file 4: Figure S4. Coverage probabilities of the 95%
confidence interval for the inconsistency factor (IF), frequency of events
and loop sample size. We assume different number of trials (K) per
comparison (KAB = 1, KAC = 4, KBC = 7). Results are aggregated over
different assumptions for the heterogeneity and methods to estimate the
variances of the mean treatment effects. The region within the horizontal
dotted lines defines the confidence interval for the 95% nominal level.
Additional file 5: Figure S5. Averaged relative bias assuming various
scenarios for the inconsistency factor, the frequency of events and loop
sample size. We assume equal number of trials per comparison
(KAB = KAC = KBC = K = 1, …, 7). Results are aggregated over different
assumptions for the heterogeneity and methods to estimate the
variances for the direct treatment effects. IF: inconsistency factor.
Additional file 6: Figure S6. Averaged relative bias assuming various
scenarios for the inconsistency factor, the frequency of events and loop
sample size. We assume different number of trials (K) per comparison
(KAB = 1, KAC = 4, KBC = 7). Results are aggregated over different
assumptions for the heterogeneity and methods to estimate the
variances of the mean treatment effects. IF: inconsistency factor.
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